alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think that for most of these indications patients are going to be seeing their doctor quarterly anyway. So the value proposition here is simply less shots as opposed to fewer doctor visits.
Good to know, picked up
Some MORE In IRA sub $31
A person on the call said that they think investors are worried about reorders and that management sounded "guarded" about Q1.
RVNC down over 10% on zero news. That is life when you invest in Biotech. Is there some kind of rebalancing going on?
New PR and this POS is down!
I wonder if it's a little like Viking (VKTX). 11 months ago it was trading at $2.22;
$16.39 right now.
Well, I can dream, : )
ENTA's anti-RSV drugs EDP-323 gets fast track designation. The tortoise that is ENTA continues its painfully slow march towards success and profit for investors.
https://finance.yahoo.com/news/enanta-pharmaceuticals-receives-fda-fast-110000666.html
"We find that a live attenuated vaccine prevents virus replication" — so "this could be a game changer in controlling SARS-CoV-2 transmission."
Those were some very interesting trading times as there was a lot of uncertainty. Being invested in Enanta was like being in a small plane in storm; lots of rises and falls. : )
Let's review. Jake wrote this asinine comment.
I could find some advil in my medicine cabinet that would also not show inferiority to Paxlovid in today’s world.
Sure. It’s called seropositivity.
Ad Revenue dropped about 10% from ‘21 to ‘22. Where are you getting revenue figures for ‘23?
I find less opinions from celebrities a feature, not a bug.
Deflectors on maximum. Hey self-proclaimed expert, why don't you address your asinine comment? You ACTUALLY wrote the following.
I could find some advil in my medicine cabinet that would also not show inferiority to Paxlovid in today’s world.
It’s not going to beat placebo. The entire world is seropositive, no one here has addressed this. For prophylaxis, you have to beat placebo.
These aren’t controlled animal studies.
And they are expensive.
With all due respect- baseless and personal attacks won’t be tolerated here.
I could find some advil in my medicine cabinet that would also not show inferiority to Paxlovid in today’s world.
The cost of subscribing to Twitter is quite modest, but many people I've talked to won't do it because they don't want help Musk in any way.
It sure looks like the "super genius" Musk is doing all he can to destroy Twitter. He is doing that job extremely well.
Wile E. Musk, super genius.
Again- where is the animal efficacy data? They must have it.
I could find some advil in my medicine cabinet that would also not show inferiority to Paxlovid in today’s world.
This is why I believe it was a joke from the start. Safety as a primary for dose ranging in this indication at this time is absurd.
And on stat sig, unvax vs. vax: hope they enrolled in a third world country. There is just no chance. Not to mention seropositivity in the unvax pts!
However, I give PRDS credit for acknowledging failure and terminating the program, unlike what AVIR did after getting a bad phase-2 result in their own COVID program.
PRDS terminates COVID antiviral program—one fewer competitor for ENTA:
The data for the phase 2 trial of EDP-235 is idea a month of 2.
For me, the links don’t appear if I use the iHub app, but they do if I log in using a browser, Chrome, Firefox and Safari all work to display links on my iPhone.
I don't see the link either.
I can never see the links posted. Anyone know why?
What about negative recommendations? Has reading this board helped you avoid buying any biotech scams or losers?
40? Now 38. Look out below
Each platform has its strengths and weaknesses. Twitter gives you exposure to many more biotech investors and biotech gurus than you can get on this board, but Twitter is also rather awkward when it comes to having an in-depth discussion.
Like I've said, nothing ever change with this POS. I'm quite sure that once the anchor is released, the ship will crash onto the rocky shore!
The title of the article is "SARS-CoV-2 furin cleavage site was not engineered".
https://www.pnas.org/doi/10.1073/pnas.2211107119
I am confused about your comments regarding the Atlantic Article. Are you saying the data was pulled from the database or they access to the database was pulled? Are you saying the Gao paper was in Bioarchives (bioRxiv.org) as a preprint and they misused or misrepresented that data?
I agree that EXEL seems quite undervalued but as a longtime holder, i find the buyback announcement rather disappointing. Shouldn't a biotech R and D company have some better way to invest their cash?
EXEL authorizes $550M share buyback for remainder of 2023:
To me, as a trained virologist who is currently working in virology and spent most of 2020 and 2021 on COVID work, the idea that COVID-19 didn't come from a lab beggars belief. This is independent of political leanings as mine are definitely not those of politicians promoting the lab leak theory.
It's really quite simple statistics -- the chance of a new and highly virulent virus emerging independently *in the same city* that houses a lab studying coronaviruses is almost impossibly low.
Keep trying. Better yet, stop.
Predicting the animal hosts of coronaviruses from compositional biases of spike protein and whole genome sequences through machine learning
You can make probabilistic arguments about codon usage all you like, but you are missing the elephant in the room. If it was an engineered virus with a few changes, then the parent virus would be well known. We don’t know about any such beast so spew your conspiracy theories all you like.
As far as which ARG codon is common in coronaviruses, it depends on the virus and the host. The virus would adapt to the host and we don’t know the natural host (i.e. the animal reservoir) so your probabilistic argument is meaningless.
Codon usage changes naturally in viruses, including in SARS-Cov2. Strong preference isn't an absolute
https://www.sciencedirect.com/science/article/pii/S0042682222000186?casa_token=O9xG3w4PuzEAAAAA:DOkygd727KXfP1hlHe2b8CnlXOpjs3bK1m0as9BfieCCmfedYzAot9O_c6nAQvbxtpfHs5PELw
As for the supposed "smoking gun", the Furin cleavage site..., the title of the linked paper is
SARS-CoV-2 furin cleavage site was not engineered
Nope.
From listening to the FDA adcomm on Paxlovid today it’s evident that clinicians desperately want an oral COVID antiviral that’s better and safer (fewer DDIs) than Paxlovid.
POS couldn't hold 19, or 18. Won't hold 17 and will head much lower. Same old story!
Enzolytics has One that is Less toxic with no side effects.